Search Results - "Dalby Kristensen, Steen"

Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus - and Sirolimus -Eluting Stents (from the SORT OUT IV Trial) by Jensen, Lisette Okkels, MD, DMSci, PhD, Thayssen, Per, MD, DMSci, Junker, Anders, MD, PhD, Maeng, Michael, MD, PhD, Tilsted, Hans-Henrik, MD, Kaltoft, Anne, MD, PhD, Hansen, Knud Nørregaard, MD, Christiansen, Evald Høj, MD, PhD, Kristensen, Steen Dalby, MD, DMSci, Ravkilde, Jan, MD, DMSci, Madsen, Morten, MSc, Sørensen, Henrik Toft, MD, DMSci, PhD, Thuesen, Leif, MD, DMSci, Lassen, Jens Flensted, MD, PhD

“…Diabetes is associated with increased risk of major adverse cardiac events (MACEs) after percutaneous coronary intervention. The purpose of this substudy of…”
Get full text

Pharmacogenetics of the antiplatelet effect of aspirin by Würtz, Morten, Kristensen, Steen Dalby, Hvas, Anne-Mette, Grove, Erik Lerkevang

“…The concept of "pharmacogenetics" addresses genetically determined variation in how individuals respond to drugs. Accordingly, specific genetic variants have…”
Get more information

Time to Treatment and Three-Year Mortality After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction—a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) Substudy by Maeng, Michael, MD, PhD, Nielsen, Peter Haubjerg, MS, Busk, Martin, MD, Mortensen, Leif Spange, MSc, Kristensen, Steen Dalby, MD, DMSc, Toftegaard Nielsen, Torsten, MD, DMSc, DMSc, Andersen, Henning Rud, MD, DMSc

“…In patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (pPCI), early reperfusion is believed to…”
Get full text

10-Year Mortality After ST-Segment Elevation Myocardial Infarction Compared to the General Population by Thrane, Pernille Gro, Olesen, Kevin Kris Warnakula, Thim, Troels, Gyldenkerne, Christine, Hansen, Malene Kærslund, Stødkilde-Jørgensen, Nina, Jakobsen, Lars, Bødtker Mortensen, Martin, Dalby Kristensen, Steen, Maeng, Michael

“…ST-segment elevation myocardial infarction (STEMI) is associated with high early mortality. However, it remains unclear if patients surviving the early phase…”
Get full text

Quantitative flow ratio for immediate assessment of nonculprit lesions in patients with ST‐segment elevation myocardial infarction—An iSTEMI substudy by Sejr‐Hansen, Martin, Westra, Jelmer, Thim, Troels, Christiansen, Evald Høj, Eftekhari, Ashkan, Kristensen, Steen Dalby, Jakobsen, Lars, Götberg, Matthias, Frøbert, Ole, Hoeven, Nina W., Holm, Niels Ramsing, Maeng, Michael

“…Objectives We evaluated the diagnostic performance of quantitative flow ratio (QFR) assessment of nonculprit lesions (NCLs) based on acute setting angiograms…”
Get full text

Feasibility and impact of whole-body high-intensity interval training in patients with stable coronary artery disease: a randomised controlled trial by Kristiansen, Jacobina, Sjúrðarson, Tórur, Grove, Erik Lerkevang, Rasmussen, Jan, Kristensen, Steen Dalby, Hvas, Anne-Mette, Mohr, Magni

“…Exercise training reduces cardiovascular mortality and improves quality of life in CAD patients. We investigated the feasibility and impact of 12 weeks of…”
Get full text

New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes: ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease Position Paper by DE CATERINA, Raffaele, HUSTED, Steen, HUBER, Kurt, JESPERSEN, Jørgen, DALBY KRISTENSEN, Steen, LIP, Gregory Y. H, MORAIS, Joao, HVILSTED RASMUSSEN, Lars, SIEGBAHN, Agneta, VERHEUGT, Freek W. A, WEITZ, Jeffrey I, WALLENTIN, Lars, ANDREOTTI, Felicita, ARNESEN, Harald, BACHMANN, Fedor, BAIGENT, Colin

“…Until recently, vitamin K antagonists were the only available oral anticoagulants, but with numerous limitations that prompted the introduction of new oral…”
Get full text

Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) by Torbicki, Adam, Perrier, Arnaud, Konstantinides, Stavros, Agnelli, Giancarlo, Galiè, Nazzareno, Pruszczyk, Piotr, Bengel, Frank, Brady, Adrian J B, Ferreira, Daniel, Janssens, Uwe, Klepetko, Walter, Mayer, Eckhard, Remy-Jardin, Martine, Bassand, Jean-Pierre

“…Non-thrombotic PE does not represent a distinct clinical syndrome. It may be due to a variety of embolic materials and result in a wide spectrum of clinical…”
Get full text

Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia by Pedersen, Oliver Buchhave, Grove, Erik Lerkevang, Pasalic, Leonardo, Ommen, Hans Beier, Kristensen, Steen Dalby, Hvas, Anne‐Mette

“…Summary Patients with essential thrombocythaemia (ET) have an increased risk of thromboembolic events, which may differ according to different cytoreductive…”
Get full text

Immature platelets in patients with acute coronary syndromes by Grove, Erik Lerkevang, Hvas, Anne-Mette, Kristensen, Steen Dalby

“…Platelets newly released from the bone marrow are RNA-containing and more haemostatically active than mature platelets. Immature platelets are reliably…”
Get more information

Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation by Egholm, Gro, MD, PhD, Kristensen, Steen Dalby, MD, DMSc, Thim, Troels, MD, PhD, Olesen, Kevin K.W., MD, Madsen, Morten, MSc, Jensen, Svend E., MD, PhD, Jensen, Lisette O., MD, PhD, DMSc, Sørensen, Henrik T., MD, PhD, DMSc, Bøtker, Hans E., MD, PhD, DMSc, Maeng, Michael, MD, PhD

“…Abstract Background Guidelines recommend postponing surgery for at least 6 months after treatment with a drug-eluting stent by percutaneous coronary…”
Get full text

General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease by De Caterina, Raffaele, Husted, Steen, Wallentin, Lars, Andreotti, Felicita, Arnesen, Harald, Bachmann, Fedor, Baigent, Colin, Huber, Kurt, Jespersen, Jørgen, Kristensen, Steen Dalby, Lip, Gregory Y H, Morais, João, Rasmussen, Lars Hvilsted, Siegbahn, Agneta, Verheugt, Freek W A, Weitz, Jeffrey I

“…Contrary to previous models based on plasma, coagulation processes are currently believed to be mostly cell surface-based, including three overlapping phases:…”
Get more information

Platelet aggregation is dependent on platelet count in patients with coronary artery disease by Würtz, Morten, Hvas, Anne-Mette, Kristensen, Steen Dalby, Grove, Erik Lerkevang

“…Abstract Introduction Platelet function testing in whole blood is widely used to evaluate the effect of antiplatelet agents, but it is not known whether…”
Get full text

Immature platelets and cardiovascular events in patients with stable coronary artery disease by Pedersen, Oliver Buchhave, Larsen, Sanne Bøjet, Kristensen, Steen Dalby, Hvas, Anne-Mette, Grove, Erik Lerkevang

“…Many patients with coronary artery disease (CAD) have reduced the effect of aspirin, which may partly be explained by immature platelets. We aimed to…”
Get full text

Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial by Christiansen, Evald Høj, Dr, Jensen, Lisette Okkels, DMSci, Thayssen, Per, DMSci, Tilsted, Hans-Henrik, MD, Krusell, Lars Romer, MD, Hansen, Knud Nørregaard, MD, Kaltoft, Anne, PhD, Maeng, Michael, PhD, Kristensen, Steen Dalby, Prof, Bøtker, Hans Erik, Prof, Terkelsen, Christian Juhl, DMSci, Villadsen, Anton Boel, MD, Ravkilde, Jan, DMSci, Aarøe, Jens, MD, Madsen, Morten, MSc, Thuesen, Leif, DMSci, Lassen, Jens Flensted, PhD

“…Summary Background Third-generation biodegradable polymer drug-eluting stents might reduce the risk of stent thrombosis compared with first-generation…”
Get full text

Long‐term outcomes after coronary intervention with biodegradable polymer stents in patients with acute coronary syndromes by Noori, Manijeh, Christiansen, Evald Høj, Raungaard, Bent, Junker, Anders, Christensen, Martin Kirk, Kahlert, Johnny, Maeng, Michael, Freeman, Phillip, Hansen, Kirstine Nørregaard, Terkelsen, Christian Juhl, Ellert‐Gregersen, Julia, Kristensen, Steen Dalby, Veien, Karsten Tange, Jakobsen, Lars, Jensen, Lisette Okkels

“…Background Patients with acute coronary syndromes (ACS) may have worse outcomes after percutaneous coronary intervention compared to patients without ACS. Aims…”
Get full text

Antiplatelet agents for the treatment and prevention of atherothrombosis by Patrono, Carlo, Andreotti, Felicita, Arnesen, Harald, Badimon, Lina, Baigent, Colin, Collet, Jean-Philippe, De Caterina, Raffaele, Gulba, Dietrich, Huber, Kurt, Husted, Steen, Kristensen, Steen Dalby, Morais, João, Neumann, Franz-Josef, Rasmussen, Lars Hvilsted, Siegbahn, Agneta, Steg, Philippe-Gabriel, Storey, Robert F, Van de Werf, Frans, Verheugt, Freek

“…The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American…”
Get full text

Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial by Raungaard, Bent, Dr, Jensen, Lisette Okkels, DMSci, Tilsted, Hans-Henrik, MD, Christiansen, Evald Høj, PhD, Maeng, Michael, PhD, Terkelsen, Christian Juhl, DMSci, Krusell, Lars Romer, MD, Kaltoft, Anne, PhD, Kristensen, Steen Dalby, Prof, Bøtker, Hans Erik, Prof, Thuesen, Leif, DMSci, Aarøe, Jens, MD, Jensen, Svend Eggert, PhD, Villadsen, Anton Boel, MD, Thayssen, Per, DMSci, Veien, Karsten Tange, MD, Hansen, Knud Nørregaard, MD, Junker, Anders, MD, Madsen, Morten, MSc, Ravkilde, Jan, DMSci, Lassen, Jens Flensted, PhD

“…Summary Background New-generation drug-eluting coronary stents have reduced the risk of coronary events, especially in patients with complex disease or…”
Get full text

New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes by De Caterina, Raffaele, MD, PhD, Husted, Steen, MD, DSc, Wallentin, Lars, MD, PhD, Andreotti, Felicita, MD, PhD, Arnesen, Harald, MD, Bachmann, Fedor, MD, Baigent, Colin, MD, Huber, Kurt, MD, Jespersen, Jørgen, MD, DSc, Kristensen, Steen Dalby, MD, Lip, Gregory Y.H., MD, Morais, João, MD, Rasmussen, Lars Hvilsted, MD, PhD, Siegbahn, Agneta, MD, PhD, Verheugt, Freek W.A., MD, Weitz, Jeffrey I., MD

“…Until recently, vitamin K antagonists were the only available oral anticoagulants, but with numerous limitations that prompted the introduction of new oral…”
Get full text

Platelet turnover in stable coronary artery disease - influence of thrombopoietin and low-grade inflammation by Larsen, Sanne Bøjet, Grove, Erik Lerkevang, Hvas, Anne-Mette, Kristensen, Steen Dalby

“…Newly formed platelets are associated with increased aggregation and adverse outcomes in patients with coronary artery disease (CAD). The mechanisms involved…”
Get full text